CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul Shaughnessy, Armin Ghobadi, Michael Bishop, Ana Alfonso Piérola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William B. Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant-Cohen, Richard T. Maziarz, Carlos Bachier
Topics & Concepts
CRISPRLymphomaRefractory (planetary science)MedicineB-cell lymphomaSalvage therapyOncologyInternal medicineChemotherapyBiologyGeneBiochemistryAstrobiologyCAR-T cell therapy research